ALFA Finder| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 3770.6 | 3900.6 | 3256.2 |
| Other income | 189.1 | 44.5 | 11.7 |
| Total income | 3959.7 | 3945.1 | 3267.9 |
| Profit before exceptional items & tax | 761.2 | 718.3 | 380.8 |
| Exceptional items | 373.4 | 184.3 | 372.8 |
| Profit before tax | 387.8 | 534.0 | 8.0 |
| Net profit | 301.3 | 403.2 | 4.4 |
| Operating margin | 9.8% | 13.5% | 0.2% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +6747.70% |
|---|---|
| Net profit, quarter on quarter | -25.30% |
| Revenue, year on year | +15.80% |
BSE results filing, NSE: GLENMARK. Figures extracted from the filing.
Glenmark Pharmaceuticals Ltd: key numbers
- Share price
- ₹2,659.50
- Market cap
- ₹75,058 Cr
- Revenue (annual)
- ₹16,983 Cr
- Net profit (annual)
- ₹1,362 Cr
- P/E (TTM)
- 51.7×Sector 43.8×
- Promoter holding
- 46.65%+0.00% QoQ
- FII holding
- 21.51%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Glenmark Pharmaceuticals Ltd
All →Glenmark Pharmaceuticals Earnings Call Transcript: Key Takeaways
Like-for-like growth ~20% and ex-IGI EBITDA margin 21%, yet H1 operating cash was negative; H2 cash recovery is the test.
Glenmark Pharmaceuticals Investor Presentation: Key Takeaways
Q2 FY27 consolidated revenue Rs 42,473 Mn, down 29.8% YoY on a reported basis. EBITDA Rs 8,638 Mn (20.3% margin); Adj PAT Rs 4,852 Mn (11.4% margin). North America headline is flattered by ISB 2001 licensing income.
Glenmark Pharmaceuticals Results Update
Glenmark Pharmaceuticals released its Q2 FY27 press release and MD&A for the quarter ended September 2026. Highlights show India growth and lower North America revenue.
Glenmark Pharmaceuticals Q2 FY27 Results: Net Profit ₹263.8 Cr, Down 56.8% YoY
Glenmark Pharmaceuticals Ltd reported revenue from operations of ₹4,247 Cr (-29.8% YoY) and net profit of ₹263.8 Cr (-56.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹263.8 Cr · -56.8% YoY
Glenmark Pharmaceuticals Other Announcement
Glenmark's partner IGI will present updated Phase 1 clinical data for ISB 2001 (ABBV-2001) in relapsed/refractory multiple myeloma at the 68th ASH Annual Meeting. The presentation is scheduled for December 12, 2026.
Glenmark Pharmaceuticals Board Meeting Date
Glenmark Pharmaceuticals notified BSE of a board meeting on 05 Nov 2026 to consider unaudited Q2 FY27 results. No financial figures are disclosed in this advance intimation.